Dolutegravir/rilpivirine for the treatment of HIV-1 infection

References

• Centers for Disease Control and Prevention [homepage on the Internet]HIV Surveillance Report: Diagnoses of HIV Infection in the United States and Dependent Areas2016 Available from: https://www.cdc.gov/hiv/statistics/overview/index.htmlAccessed January 18, 2018
   Google Scholar
• UNAIDSGlobal report 2013: UNAIDS report on the global AIDS epidemic2013 Available from: https://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdfAccessed January 18, 2018
   Google Scholar
• UNAIDSAIDS by the numbers Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2013/JC2571_AIDS_by_the_numbers_en.pAccessed February 2, 2018
   Google Scholar
• AmbrosioniJCalmyAHirschelBHIV treatment for preventionJ Int AIDS Soc2011142821612619
   PubMed Web of Science ®Google Scholar
• UNAIDSGlobal HIV/AIDS response: epidemic update and health sector progress towards universal accessProgress report2011 Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20111130_ua_report_en.pdfAccessed February 10, 2018
   Google Scholar
• Lactic Acidosis International Study GroupRisk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapyAIDS200721182455246418025882
   PubMed Web of Science ®Google Scholar
• Arenas-PintoABhaskaranKDunnDWellerIVThe risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trialAntivir Ther20081328929518505180
   PubMed Web of Science ®Google Scholar
• KozalMLupoSDeJesusEA Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study ResultsHIV Clin Trials201213311913022592092
   PubMed Web of Science ®Google Scholar
• SterneJAHernánMALedergerberBLong-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort studyLancet2005366948337838416054937
   PubMed Web of Science ®Google Scholar
• TaiwoBZhengLGallienSEfficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)AIDS201125172113212221857490
   PubMed Web of Science ®Google Scholar
• TaiwoBMarconiVDolutegravir plus lamivudine maintain human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trialCID20181117941797
   Web of Science ®Google Scholar
• MargolisDAGonzalez-GarciaJStellbrinkHJLong-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trialLancet2017390101011499151028750935
   PubMed Web of Science ®Google Scholar
• BorghettiABaldinGLombardiFEfficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replicationHIV Med2018197452454
   Web of Science ®Google Scholar
• PasquauJHidalgo-TenorioCNuke-Sparing Regimens for the Long-Term Care of HIV InfectionAIDS Rev201517422023026679853
   PubMed Web of Science ®Google Scholar
• AchhraACBoydMAAntiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literatureAIDS Res Ther20131013324330617
   PubMed Web of Science ®Google Scholar
• FDA [homepage on the Internet]FDA approved first two-drug regimen for certain patients with HIV Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm586305.htmAccessed February 1, 2018
   Google Scholar
• MitusaHWeinholdK3′-Azido-3′deoxythimidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphothrotic virus type III/lymphadenopathy-associated virus in vitroProc Natl Acad Sci19859270967100
   Web of Science ®Google Scholar
• HammerSMSquiresKEHughesMDA controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study TeamN Engl J Med1997337117257339287227
   PubMed Web of Science ®Google Scholar
• StaszewskiSMorales-RamirezJTashimaKTEfavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 TeamN Engl J Med1999341251865187310601505
   PubMed Web of Science ®Google Scholar
• KnechtenHLutzTPulikPMartinTTappeAJaegerHSafety and Efficacy in HIV-1-Infected Patients Treated with Ritonavir-Boosted Saquinavir MesylateArch Drug Inf201031263620428230
   PubMedGoogle Scholar
• Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and AdolescentsGuidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Available from: http://www.aidsinfo.nih.gov/ContentFiles/Adultand-AdolescentGL.pdfAccessed January 8, 2018
   Google Scholar
• PalellaFJDelaneyKMMoormanACDeclining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study InvestigatorsN Engl J Med1998338138538609516219
   PubMed Web of Science ®Google Scholar
• PubchemStructure of dolutegravir sodium Available from: https://pub-chem.ncbi.nlm.nih.gov/compound/46216142#section=TopAccessed February 8, 2018
   Google Scholar
• PodanyATScarsiKKFletcherCVComparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer InhibitorsClin Pharmacokinet2017561254027317415
   PubMed Web of Science ®Google Scholar
• KandelCWalmsleySDTG – a review of the pharmacology, efficacy, and safety in the treatment of HIVDrug Des Devel Ther2015935473555
   PubMed Web of Science ®Google Scholar
• CottrellMLHadzicTKashubaADClinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravirClin Pharmacokinet2013521198199423824675
   PubMed Web of Science ®Google Scholar
• GSKDolutegravir and rilpivirine for Oral use: Highlights of Prescribing information. Juluca®[package insert]GlaxoSmithKline Inc2017 Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Juluca/pdf/JULUCA-PI-PIL.PDFAccessed February 10, 2018
   Google Scholar
• GSKDolutegravir tablets for oral use: Highlights of Prescribing information.Tivicay®(DTG) [package insert] Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tivicay/pdf/TIVICAY-PI-PIL.PDFAccessed February 10, 2018
   Google Scholar
• Janssen TherapeuticsRilpivirine tablets for oral use: Highlights of Prescribing InformationEdurant®(RPV) [package insert] Available from: http://www.edurant.com/shared/prescribing-information-edurant.pdfAccessed February 10, 2018
   Google Scholar
• PubchemStructure of rilpivirine hydrochloride Available from: https://pubchem.ncbi.nlm.nih.gov/compound/11711114#section=TopAccessed February 8, 2018
   Google Scholar
• van HeeswijkRHoetelmansRThe effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI)Poster presented at: The Seventh International Workshop of Clinical PharmacologyApril 20–22, 2006Lisbon, Portugal
   Google Scholar
• FordNLeeJAndrieux-MeyerICalmyASafety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settingsHIV AIDS201133544
   Google Scholar
• OgbuaguORilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patientsExpert Rev Anti Infect Ther201614121113112627797606
   PubMed Web of Science ®Google Scholar
• CohenCJMolinaJMEfficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE TrialsJ Aquir Immune Defic Syndr20121601)3342
   PubMed Web of Science ®Google Scholar
• CrauwelsHVingerhoetsJRyanRWitekJAndersonDPharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjectsAntivir Ther201217343944622293086
   PubMed Web of Science ®Google Scholar
• LlibreJMHungCCBrinsonCEfficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studiesLancet20183911012383984929310899
   PubMed Web of Science ®Google Scholar
• CapettiAFSterrantinoGCossuMVSwitch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational CohortPLoS One20161110e016475327741309
   PubMed Web of Science ®Google Scholar
• LindemanTADugganJMSahloffEGEvaluation of Serum Creatinine Changes With Integrase Inhibitor Use in Human Immunodeficiency Virus-1 Infected AdultsOpen Forum Infect Dis201632ofw05327092314
   PubMed Web of Science ®Google Scholar
• GantnerPCuzinLAllavenaCEfficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort studyHIV Med201718970470828444816
   PubMed Web of Science ®Google Scholar
• Juluca [homepage on the Internet]European Medicines Agency -Human medicines - Juluca Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004427/smops/Positive/human_smop_001278.jsp&mid=WC0b01ac058001d127Accessed April 23, 2018
   Google Scholar
• WalmsleySBaumgartenADolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trialJ Acquir Immune Defic Syndr20157051551926262777
   PubMed Web of Science ®Google Scholar
• RaffiFJaegerHQuiros-RoldanEOnce-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trialLancet Infect Dis2013131192793524074642
   PubMed Web of Science ®Google Scholar
• MolinaJMClotetBvan LunzenJOnce-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b studyLancet HIV201524e127e13626424673
   PubMed Web of Science ®Google Scholar
• CohenCJAndrade-VillanuevaJClotetBRilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialLancet2011378978722923721763935
   PubMed Web of Science ®Google Scholar
• DhodyKPourhassanNKazempourKPRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infectionHIV Clin Trials2018193859329676212
   PubMed Web of Science ®Google Scholar
• PatelPSongIBorlandJPharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteersJ Antimicrob Chemother20116671567157221493648
   PubMed Web of Science ®Google Scholar